1 Min Read
April 13 (Reuters) - Nabriva Therapeutics Ag-
* Nabriva Therapeutics to present data at eccmid supporting ongoing phase 3 clinical development program for lefamulin Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.